Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

Authors:

Abstract
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. Though, corticosteroids are the cornerstone of therapy, the Janus kinase inhibitor abrocitinib has shown promise in recent ...

This publication has 26 references indexed in Scilit: